KIORA PHARMACEUTICALS INC (KPRX) Stock Analyst Earnings Estimates
NASDAQ:KPRX - Nasdaq - US49721T5074 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.65M 302.44% | 2.69M 63.03% | 10K -99.63% | -100.00% | 17.095M | 3.06M -82.10% | 1.53M -50.00% | -100.00% | 19.058M | 90.864M 376.78% | 234.86M 158.47% | 502.63M 114.01% | 638.63M 27.06% | |||
| EBITDA YoY % growth | -10.8M 25.72% | -7.06M 34.63% | -8.18M -15.86% | N/A -24.08% | N/A -20.89% | N/A 13.36% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -10.84M 25.55% | -7.11M 34.41% | -8.21M -15.47% | -11.411M -24.24% | -13.299M -20.69% | -13.728M 13.22% | 5.07M 147.46% | -12.593M -348.39% | -21.676M -72.12% | -22.78M -5.09% | -6.042M 73.48% | 59.28M 1,081.14% | 190.19M 220.83% | 88.697M -53.36% | 237.5M 167.77% | |
| Operating Margin | -656.97% | -264.31% | -82,100.00% | N/A | N/A | N/A | 29.66% | -411.55% | -1,416.73% | N/A | -31.70% | 65.24% | 80.98% | 17.65% | 37.19% | |
| EPS YoY % growth | -1,782.00 65.26% | N/A 56.93% | N/A 3.35% | -455.33 18.86% | -123.56 61.43% | -23.43 87.79% | 0.88 103.11% | -2.54 -388.44% | -2.59 -1.80% | -1.07 58.66% | -0.19 81.90% | 5.65 3,015.79% | 16.49 191.88% | N/A | N/A |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.56 86.74% | -0.68 -119.98% | -0.69 -30.87% | -0.71 11.85% | -0.59 -4.55% |
| Revenue Q2Q % growth | 765K | -100.00% | -100.00% | -100.00% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.147M -1.32% | -3.58M -127.08% | -3.705M -45.57% | -3.834M -140.50% | -3.969M -84.89% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.81 89.89% | -0.78 | -0.03 | -3.94% |
| Q2 2024 Q2Q % growth | -0.53 92.55% | -0.87 | 0.34 | 39.35% |
| Q1 2024 Q2Q % growth | 3.42 138.00% | -0.61 | 4.03 | 664.47% |
| Q4 2023 Q2Q % growth | -4.23 73.25% | -3.84 | -0.39 | -10.10% |
| Q3 2023 Q2Q % growth | -8.01 85.25% | -3.24 | -4.77 | -146.95% |
| Q2 2023 Q2Q % growth | -7.11 89.03% | -9.78 | 2.67 | 27.31% |
| Q1 2023 Q2Q % growth | -9.00 90.74% | -15.47 | 6.47 | 41.82% |
| Q4 2022 Q2Q % growth | -15.81 93.36% | -22.58 | 6.77 | 29.97% |
| Q3 2022 Q2Q % growth | -54.30 47.99% | -35.21 | -19.09 | -54.23% |
| Q2 2022 Q2Q % growth | -64.80 48.57% | -73.44 | 8.64 | 11.76% |
| Q1 2022 Q2Q % growth | -97.20 27.03% | -86.29 | -10.91 | -12.64% |
| Q4 2021 Q2Q % growth | -238.26 -27.27% | -84.46 | -153.80 | -182.11% |
| Q3 2021 Q2Q % growth | -104.40 34.09% | -123.63 | 19.23 | 15.55% |
| Q2 2021 Q2Q % growth | -126.00 7.89% | -153.00 | 27.00 | 17.65% |
| Q1 2021 Q2Q % growth | -133.20 | -141.37 | 8.17 | 5.78% |
| Q4 2020 Q2Q % growth | -187.20 27.27% | -161.57 | -25.63 | -15.86% |
| Q3 2020 Q2Q % growth | -158.40 | -154.22 | -4.18 | -2.71% |
| Q2 2020 Q2Q % growth | -136.80 36.67% | -157.90 | 21.10 | 13.36% |
| Q4 2019 Q2Q % growth | -257.40 | -297.43 | 40.03 | 13.46% |
| Q2 2019 Q2Q % growth | -216.00 | -275.40 | 59.40 | 21.57% |
| Q1 2019 Q2Q % growth | 54.00 | -275.40 | 329.40 | 119.61% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 7.14K | -7.14K | -100.00% | |
| Q4 2021 Q2Q % growth | -100.00% | % | ||
| Q1 2020 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 8.33% | 24.55% | 21.26% | -35.78% |
| Revenue | 50% | 50% | 1.49% | 1.4% |